#CANF↓

CANF/ 03/04/2026 · 8:15 AM

Can-Fite’s Namodenoson Shows Strong Safety Profile in Advanced Pancreatic Cancer Patients

Can-Fite BioPharma shares positive Phase 2a results for Namodenoson in treating advanced pancreatic cancer, highlighting its safety and potential for better survival outcomes in tough cases.

CANF/ 12/26/2025 · 8:27 AM

Can-Fite Secures Brazilian Patent for Sexual Dysfunction Treatment

Can-Fite BioPharma receives Brazilian patent protection for its A3 adenosine receptor agonist drug targeting sexual dysfunction, expanding its presence in Latin America's pharmaceutical market.